Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)

National Comprehensive Cancer Network Hopwood, 1995, Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party, Br J Cancer, 71, 633, 10.1038/bjc.1995.124 Lutz, 2001, Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using the Lung Cancer Symptom Scale in a community hospital, J Palliat Med, 4, 157, 10.1089/109662101750290191 Li, 2004, Quality of life after lung cancer resection, Thorac Surg Clin, 14, 353, 10.1016/S1547-4127(04)00023-4 Shaw, 2011, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, Lancet Oncol, 12, 1004, 10.1016/S1470-2045(11)70232-7 Rosell, 2012, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Fidias, 2010, Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer, J Clin Oncol, 28, 5116, 10.1200/JCO.2010.30.7074 Azzoli, 2011, 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer, J Clin Oncol, 29, 3825, 10.1200/JCO.2010.34.2774 Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884 Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375 Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5 Paz-Ares, 2012, Lancet Oncol, 13, 247, 10.1016/S1470-2045(12)70063-3 Behera, 2011, Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: a meta-analysis, J Clin Oncol, 29, 489s Zhang, 2011, Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis, Chest, 140, 117, 10.1378/chest.10-2745 Sandler, 2011, Clinical patterns and outcomes for the bevacizumab maintenance population in the ECOG 4599 study of patients with advanced non–small cell lung cancer (NSCLC): results of an exploratory analysis, J Thorac Oncol, 6, s1309 Kosty, 2011, Cumulative exposure to bevacizumab (BV) after induction therapy (tx) correlates with increased survival in patients (pts) with non-small cell lung cancer (NSCLC), Eur J Cancer, 47, 619, 10.1016/S0959-8049(11)72402-9 Kosty, 2011, Use of bevacizumab (BV) after induction therapy is associated with survival benefit in patients (pts) with non-small cell lung cancer (NSCLC) in the ARIES observational cohort study (OCS), Eur J Cancer, 47, 598, 10.1016/S0959-8049(11)72332-2 Kabbinavar, 2010, J Clin Oncol, 28, 544s Barlesi F, Scherpereel A, Rittmeyer A, et al. A randomized phase III trial of maintenance bevacizumab with or without pemetrexed following first-line induction with bevacizumab–cisplatin–pemetrexed in advanced nonsquamous non–small cell lung cancer: AVAPERL (MO22089). J Clin Oncol. In press Rittmeyer, 2013, Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial, J Clin Oncol, 31, 489s Ahn M, Gervais R, Mezger J, et al. AVAPERL (MO22089)—interim safety of maintenance (mtc) bevacizumab (bev) + pemetrexed (pem) in patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) after first-line (1L) bev-cisplatin (cis)-pem treatment (tx). Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23–27, 2011. Poster 9112. Aaronson, 1993, The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology, J Natl Cancer Inst, 85, 365, 10.1093/jnci/85.5.365 Bergman, 1994, The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life, Eur J Cancer, 30A, 635, 10.1016/0959-8049(94)90535-5 Beckles, 2003, Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes, Chest, 123, 97S, 10.1378/chest.123.1_suppl.97S Cooley, 2003, Symptom prevalence, distress, and change over time in adults receiving treatment for lung cancer, Psychooncology, 12, 694, 10.1002/pon.694 Osoba, 1998, Interpreting the significance of changes in health-related quality-of-life scores, J Clin Oncol, 16, 139, 10.1200/JCO.1998.16.1.139 Claassens, 2011, Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials, J Clin Oncol, 29, 2104, 10.1200/JCO.2010.32.3683 Beitz, 1996, Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective, J Natl Cancer Inst Monogr, 20, 7 American Society of Clinical Oncology, 1996, Outcomes of cancer treatment for technology assessment and cancer treatment guidelines, J Clin Oncol, 14, 671, 10.1200/JCO.1996.14.2.671 Silvestri, 1998, Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews, BMJ, 317, 771, 10.1136/bmj.317.7161.771 Cella, 2008, Improving health-related quality of life in non-small-cell lung cancer with current treatment options, Clin Lung Cancer, 9, 206, 10.3816/CLC.2008.n.030 Gridelli, 2011, Clin Lung Cancer, 12, 407, 10.1016/j.cllc.2011.05.002 Patel, 2009, Clin Lung Cancer, 10, 252, 10.3816/CLC.2009.n.035 Galetta, 2011, Clin Lung Cancer, 12, 402, 10.1016/j.cllc.2011.06.006 Efficace, 2006, Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975, Ann Oncol, 17, 1698, 10.1093/annonc/mdl183 Temel, 2010, Early palliative care for patients with metastatic non-small-cell lung cancer, N Engl J Med, 363, 733, 10.1056/NEJMoa1000678